Skyhawk Therapeutics have received the regulatory approval needed to broaden its FALCON-HD trial to include the United States, Canada, and the UK. The expanded trial will enroll up to 400 more people with Stage 2 and early Stage 3 HD across more than 40 sites worldwide.

Roche announced it is stopping development of two of its huntingtin-lowering ASO drugs, tominersen and RG6496. This marks a disappointing end to an important chapter in HD clinical research. en.hdbuzz.net/roche-ends-two…

First participant dosed in pioneering neural stem cell trial for Huntington’s disease A new clinical trial for HD is underway. The first participant has been dosed in REGEN4HD, a study testing whether transplanting neural stem cells is safe as a potentia… ift.tt/LTCh07A

Evolving Needs, Evolving Care: Adapting Psychological Support Across Different Stages of Huntington’s Disease ⏱️ 9 min read | Huntington’s disease affects more than movement: it also has a major impact on mental health. Researchers explore why psychologi… ift.tt/g8CA3PV

Sealing the gap: a case for slower, smarter DNA repair ⏱️ 7 min read | Your body assembles DNA like a team of workers who set and bond a pattern of tiles. A recent study shows that one special assistant might slow somatic CAG expansion and delaying HD on… ift.tt/mnjeTal

HDBuzz 2025 Annual Report: Here’s what you made possible ⏱️7 min read | In 2025, you helped us reach 329,000 people with independent, unbiased HD research news. Our 2025 Annual Report is here. Take a look at what we built together, and consider helping u… ift.tt/mle90Db

Skyhawk reports encouraging 12-month results for oral Huntington’s disease drug SKY-0515 One year into treatment, SKY-0515 continues to lower huntingtin and shows encouraging trends with signs and symptoms of HD. A larger trial is enrolling to determine … ift.tt/rendJCp

May 2026: This Month in Huntington’s Disease Research ⏱️8 min read | May 2026: 2 year data from the votoplam trial suggests disease progression may slow; AMT-130 heads to the UK for regulatory review; pigs reveal immune cells invading the HD brain; and n… ift.tt/xIgKGi8

Fixing the Recipe: Lowering a Slice of Huntingtin ⏱️7 min read | In a recent paper, scientists targeted a small, harmful piece of the huntingtin message (HTT1a) in HD mice. This reduced toxic protein clumps and delayed genetic changes, more than targetin… ift.tt/ohuZJqr

Tagging the Trash: Turnover of Toxic Huntingtin  ⏱️ 5 min read | A recent study suggests that strengthening the brain's own clean-up system could slow Huntington’s disease. ift.tt/zPubeUi

Prilenia’s Application for European Approval of Pridopidine Withdrawn ⏱️ 5 min read | Prilenia's application for European approval of pridopidine was quietly withdrawn 6 months ago, in November 2025, after the EMA had already recommended refusing the dru… ift.tt/xcZXmPe

Intruders in the Brain: What a Pig Model Reveals about Immune Cells in HD ⏱️7 min read | A recent study in pigs suggests the HD brain could be under attack from the body's own immune system. The results reveal that invading cytotoxic T cells might contri… ift.tt/elk1RxY

The Great Care Conundrum: What “Good” Care Looks Like in Huntington’s Disease ⏱️8 min read | What does “good care” look like in Huntington’s Disease? A new Dutch study asked familial and professional caregivers, and uncovered how differently it’s experie… ift.tt/3x7JjEH

A Second Path: uniQure Plans Regulatory Filing for AMT-130 in the UK ⏱️ 6 min read | While the US regulatory path for AMT-130 remains complicated, uniQure announced plans to seek approval for its HD gene therapy in the UK. Here's what that means, and wha… ift.tt/D8APmok

Two Years In: New Long-Term Extension Data from PIVOT-HD for Votoplam ⏱️10 min read | PTC Therapeutics shared 2-year data for votoplam, a daily HTT-lowering pill. Stage 2 participants showed up to 52% slowing of disease progression. Here's what the data … ift.tt/Zi1FRcO

We're grateful to everyone who has donated, shared, & spread the word. We're 27% of the way to our $30,000 goal! If you've been meaning to give, now's a great time. Fund the Buzz runs through June 15. Every contribution keeps HDBuzz independent & free for HD families.

April 2026: This Month in Huntington’s Disease Research ⏱️ 8 min read | April 2026 showed us a toxic HTT fragment is center stage in mouse research, CRISPR is showing promise in mouse studies, AI and wearables move closer to the clinic, and 2 studies shi… ift.tt/sGtPyjH

The Number on the Scale: What the TFC Score Measures, and Why It Matters Right Now ⏱️ 10 min read | The Total Functional Capacity score has been used in Huntington’s disease research for decades. Here's what it measures, what it misses, & why it's at the… ift.tt/xT5cZ3L

Dancing With a Stranger: Understanding Apathy in Huntington’s Disease Through Caregivers ⏱️5 min read | Apathy in HD isn’t just “not caring.” It can affect relationships, routines, and emotional connection. A small study of caregivers reveals the heavy t… ift.tt/wh1dXRb

When the FDA made a controversial decision about the first HD gene therapy, nearly 29,000 people read our coverage - about as many visitors as we normally see in an entire month. People come to HDBuzz when it matters. Help Fund the Buzz: hdbuzz.net/donate